Cell Surface Markers Market, By Product Type (Flow Cytometers, Hematology Analyzers, Reagents and Kits), By Application (Disease Diagnosis and identification, Research/Drug Discovery), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) is estimated to be valued at US$ 31.9 Billion in 2023 and is expected to exhibit a CAGR of 8.6% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The strategies by key market players like acquisitions is expected to drive the global cell surface markers market growth over the forecast period. For instance, on December 8, 2021, Thermo Fisher Scientific Inc., a U.S-based laboratory equipment supplier, announced that it has completed its acquisition of PPD, Inc., a U.S.-based global contract research organization, for US$ 17.4 billion. The transaction is expected to contribute US$ 1.50 to Thermo Fisher's adjusted earnings per share in 2022. In connection with the acquisition, Thermo Fisher will also assume approximately US$ 3.0 billion in net debt of PPD. All assumed debt will be retired in connection with the closing of the transaction. With this expansion biotech and pharmaceutical customers of Thermo Fisher Scientific Inc. will increase due to addition of PPD's leading clinical research services. Addition of PPD, Thermo Fisher will offer a comprehensive suite of world-class services across the clinical development spectrum − from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product. This will help to bring life-changing therapies to market, benefitting patients around the world.
Global Cell Surface Markers Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and health care of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.
COVID-19 had positive impact on the global cell surface markers market due to increasing need for cell marking technique. For instance, according to an article published by Frontier in immunology on February 26, 2021, study was carried out to compare the cell surface marker expression on the monocytes of COVID-19 patients with healthy controls. The study monitored 11 COVID-19 patients with ARDS for their immune phenotype, plasma cytokines, and clinical parameters on the day of ICU admission and on day 4 and day 7 of their ICU stay. Whole blood stimulation assays with lipopolysaccharide (LPS), heat-killed Listeria monocytogenes (HKLM), Aspergillus fumigatus, and Candida albicans were used to mimic secondary infections, and changes in immune phenotype and cytokine release were assessed. COVID-19 patients displayed an immune phenotype characterized by increased HLA-DR+CD38+ and PD-1+ CD4+ and CD8+ T cells, and elevated CD8+CD244+ lymphocytes, compared to healthy controls. The study found an increased rate of fungal co-infections in COVID-19 patients. The rate of secondary fungal infections increased in many COVID-19 patients due to their decreased immunity. Such studies with help of cell markers drive growth of market.
Global Cell Surface Markers Market: Key Developments
Increasing launch of new range of products that can improve the efficacy of cell marking is expected to drive the market growth.
For instance, on June 15, 2021, Leica Microsystems, a Europe-based microscope manufacturing company announced the launch of the Leica Nano workflow: a new live-cell correlative light and electron microscopy (CLEM) workflow solution designed to increase experimental success rates, improve reproducibility, and simplify light and electron microscopy (EM) integration. The Leica Nano workflow combines high-contrast live cell imaging with EM sample preparation to provide a streamlined all-in-one workflow to answer a wide range of biological questions. Here live-cell CLEM is providing a more complete picture in contrast to most workflows that are limited either by the sample range, the transfer time or the sample conditions during imaging and fixation – increasing complexity and risk of failure. The resulting images capture cellular functional and ultrastructural information that can be easily distinguished and integrated at the single-cell level.
Browse 27 Market Data Tables and 24 Figures spread through 160 Pages and in-depth TOC on Global Cell Surface Markers Market, By Product Type (Flow Cytometers, Hematology Analyzers, Reagents and Kits), By Application (Disease Diagnosis and identification, Research/Drug Discovery), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cell-surface-markers-market-3912
Key Takeaways of the Global Cell Surface Markers Market:
- Global cell surface markers market is expected to exhibit a CAGR of 8.6 % during the forecast period. Introduction of newer products by key market players is expected to drive market growth. For instance, on February 1, 2021, Beckman Coulter, Inc., a U.S. based biomedical company, announced the launch of the DxH 560 AL, a tabletop hematology analyzer designed to reduce the time and resource constraints faced by small- to mid-sized laboratories. With the analyzer’s auto-loading functionality, closed tube aspiration and walkaway capabilities, users can continually add up to 50 samples, provide safety against blood-borne pathogens and spend less time on manual instrument tasks. The DxH 560 AL delivers results in 60 seconds or less. It can be used with difficult-to-draw patients (infants, oncology and elderly) because it only needs a 17 μL sample– less than a drop of blood. The analyzer also provides privacy and security features including customizable user login, paperless data management and fully traceable automated timeouts.
- Among product type, Flow Cytometers segment is expected to dominate the global cell surface markers market over the forecast period, owing to launch of new flow cytometers. For instance, on June 7, 2021, Thermo Fisher Scientific Inc., U.S. based laboratory equipment supplier announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera. The Attune CytPix allows users to collect high-performance fluorescent flow cytometry data from cells while simultaneously capturing high resolution brightfield images, allowing users to match images with their flow cytometry data to better understand the morphology and quality of the cells.
- Among region, North America is expected to be the dominant region in the global cell surface markers market, owing to the increasing collaboration for research in cell markers. For instance, on May 15, 2020, Beckman Coulter, Inc., a U.S. based biomedical company, partnered with National Cancer Institute (NCI) to create and evaluate a new panel of cell surface markers for use in cancer research. The panel, which includes markers for recognizing immune cells that infiltrate tumors, is meant to aid in the creation of fresh cancer immunotherapies.
- Major players operating in the global cell surface markers market include Abbott Laboratories, Inc., Beckman Coulter, Inc., BD Biosciences, Bio-Rad Laboratories, Inc., Grifols SA, Immucor, Inc., Janssen Diagnostics, Inc., Nihon Kohden Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Sysmex Corporation, and Thermo Fisher Scientific, Inc.
